Resveratrol

SIRT1 Activation and Caloric Restriction Mimicry

Resveratrol's most significant mechanism is activation of sirtuin-1 (SIRT1), a class III histone deacetylase that requires NAD+ as a co-substrate. SIRT1 is a central regulator of cellular stress responses and metabolic adaptation, sometimes described as a master longevity regulator. Direct SIRT1 activation by resveratrol (or indirectly via AMPK) produces:

• PGC-1α deacetylation and activation → mitochondrial biogenesis, fatty acid oxidation, aerobic capacity
• FOXO deacetylation → enhanced stress resistance, DNA repair
• NF-κB deacetylation → reduced inflammatory gene expression
• p53 deacetylation → modulated apoptotic responses
• Histone deacetylation → epigenetic reprogramming toward a "calorie-restricted" gene expression pattern

AMPK Activation

Resveratrol activates AMP-activated protein kinase (AMPK), the cellular energy sensor that responds to energetic stress. AMPK activation by resveratrol mimics the biochemical state of caloric restriction — inhibiting anabolic processes (fatty acid synthesis, protein synthesis, gluconeogenesis) and activating catabolic ones (fatty acid oxidation, autophagy, glucose uptake). AMPK also indirectly activates SIRT1 by increasing NAD+ availability.

Antioxidant and Anti-Inflammatory Mechanisms

• Nrf2 activation: Resveratrol activates the Nrf2-ARE pathway, upregulating glutathione, NQO1, and other cytoprotective enzymes
• COX-1/COX-2 inhibition: Anti-inflammatory effects comparable to NSAIDs at relevant concentrations
• Free radical scavenging: The hydroxyl groups on resveratrol's stilbene scaffold directly neutralize reactive oxygen species

Neuroprotective Mechanisms

• BDNF and VEGF upregulation: Promotes hippocampal neurogenesis
• Amyloid and tau modulation: Reduces amyloid-beta aggregation and tau hyperphosphorylation in model systems
• Cerebrovascular effects: Activates endothelial nitric oxide synthase (eNOS), improving cerebral blood flow

Trans vs. Cis Isomers

Trans-resveratrol (E-isomer) is the form present in grapes and red wine and is the biologically active isomer. Cis-resveratrol (Z-isomer) has substantially less activity at SIRT1 and other targets. Trans-resveratrol is isomerized to cis by UV light and heat — quality storage requires dark, cool conditions. High-quality supplements specify trans-resveratrol purity.

Bioavailability

Oral bioavailability of resveratrol parent compound is approximately 0.5–1% — the compound is absorbed but rapidly conjugated to sulfates and glucuronides in the gut and liver. Whether conjugated metabolites are biologically active is debated; some data suggests the conjugates may be deconjugated in target tissues. Micronized preparations and phospholipid complexes achieve significantly higher plasma concentrations of parent resveratrol. Co-administration with quercetin and piperine further improves absorption.

Discovery and the French Paradox

Resveratrol was first isolated from the roots of Veratrum grandiflorum (white hellebore) in 1940 by Michio Takaoka. However, it attracted little scientific interest until the 1990s. The key event was the 1992 paper by Siemann and Creasy in the American Journal of Enology and Viticulture identifying resveratrol in red wine, which connected it to earlier epidemiological observations.

The "French Paradox" — the apparently paradoxical low cardiovascular mortality of the French despite their high saturated fat consumption — was popularized by Serge Renaud and de Lorgeril in a landmark 1992 Lancet paper and received massive popular exposure through a 60 Minutes television segment in November 1992. While the paper focused on wine consumption broadly, resveratrol became the leading proposed molecular explanation. This produced a dramatic and sustained increase in red wine sales.

The SIRT1 Connection and the Longevity Wave

The scientific breakthrough that transformed resveratrol from an obscure polyphenol to a major research interest was the 2003 paper by David Sinclair and colleagues at Harvard, published in Nature, showing that resveratrol directly activates SIRT1 and extends lifespan in yeast. Subsequent papers demonstrated lifespan extension in worms (C. elegans), flies (Drosophila), and fish. A 2006 paper in Nature by Baur, Sinclair, and colleagues demonstrated that resveratrol improved health and extended lifespan in obese mice fed a high-fat diet — a finding that generated global media coverage.

Commercial and Clinical Development

These findings drove explosive commercial interest in resveratrol. A pharmaceutical company, Sirtris Pharmaceuticals, was founded by Sinclair and colleagues specifically to develop SIRT1-activating molecules including resveratrol derivatives; it was acquired by GlaxoSmithKline for $720 million in 2008. The lead drug program was ultimately discontinued due to toxicity and efficacy concerns, and the entire area of SIRT1 pharmacology became more contentious following a 2010 Nature paper questioning whether resveratrol directly activates SIRT1 or does so indirectly.

Clinical trials in humans have produced mixed results, with consistent findings primarily in metabolic and inflammatory endpoints (particularly in people with metabolic syndrome, diabetes, or inflammatory conditions). The longevity effects observed in model organisms have not been replicated in human clinical contexts — though whether this reflects the bioavailability limitation, the need for longer trials, or fundamental differences between species remains debated.